[Hydro-CT in detection and staging of pancreatic carcinoma]. 1998

G M Richter, and C Wunsch, and B Schneider, and M Düx, and E Klar, and R Seelos, and G W Kauffmann
Abteilung Radiodiagnostik, Universitätsklinik Heidelberg.

OBJECTIVE To document our experience with spiral hydro-CT of the pancreas based on a combination of pharmacologic intestinal paralysis and water distension of the stomach and duodenum with specific reference to tumor detection rate, differentiation of malignant versus benign tumors and assessment of tumor resectability in a prospective study on 211 consecutive patients. METHODS Between May 1994 und September 1997, 211 patients with suspect of pancreatic neoplasm from clinical, laboratory or other imaging data were examined. Our Hydro-CT techniques were based on intravenous injection of 40 mg N-butylscopolaminiumbromid (Buscopan) for intestinal paralysis, gastric and duodenal wall distension by oral administration of an average of 1.5 l warm tap water, 30 degrees RAO patient's positioning, individualized contrast injection technique using portal vein enhancement as reference and thin slice spiral CT (3 mm slice thickness, 6 mm table feed and 3 mm secondary reconstruction). Examined parameters were: (1) tumor detection rate, (2) differentiation of malignant versus benign disease, (3) differential diagnosis and (4) accuracy of assessment of resectability by identification of infiltration into adjacent organs and vessel structures relevant for resectability such as splenic, superior mesenteric, portal vein and celiac trunk, superior mesenteric, splenic and hepatic arteries. As gold standard for positive tumor detection and description surgery (of potentially resectable tumors) and microscopic diagnosis (of clearly unresectable tumors) were used and for negative tumor detection an event-free survival of six months, respectively. RESULTS 96% of the examinations were well tolerated. In only 4% was on-site administration of a gastric tube required because of vomiting. In 2% of the patients a slight allergic reaction to the contrast medium was seen. The prevalence of a pancreatic neoplasm was 37.8%. In tumor detection Hydro-CT reached an overall accuracy of 94.8% with a sensitivity of 93.7% and a specificity of 95.2%. 52 patients underwent surgical exploration 34 of whom with tumorfree resection margins (RO resection) corresponding to a resection of 42.5%. In those assessment of resectability reached an overall accuracy of 94.6% with a sensitivity of 91.2% and specificity of 95.6%. CONCLUSIONS The new technique of Hydro-CT based on the slice and spiral methodology including pharmacologic intestinal paralysis and water distension results in a high tumor detection rate and reliable assessment of resectability.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009361 Neoplasm Invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue. Invasiveness, Neoplasm,Neoplasm Invasion,Invasion, Neoplasm
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D010179 Pancreas A nodular organ in the ABDOMEN that contains a mixture of ENDOCRINE GLANDS and EXOCRINE GLANDS. The small endocrine portion consists of the ISLETS OF LANGERHANS secreting a number of hormones into the blood stream. The large exocrine portion (EXOCRINE PANCREAS) is a compound acinar gland that secretes several digestive enzymes into the pancreatic ductal system that empties into the DUODENUM.
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D010276 Parasympatholytics Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. Antispasmodic,Antispasmodic Agent,Antispasmodic Drug,Antispasmodics,Parasympathetic-Blocking Agent,Parasympathetic-Blocking Agents,Parasympatholytic,Parasympatholytic Agent,Parasympatholytic Drug,Spasmolytic,Spasmolytics,Antispasmodic Agents,Antispasmodic Drugs,Antispasmodic Effect,Antispasmodic Effects,Parasympatholytic Agents,Parasympatholytic Drugs,Parasympatholytic Effect,Parasympatholytic Effects,Agent, Antispasmodic,Agent, Parasympathetic-Blocking,Agent, Parasympatholytic,Agents, Antispasmodic,Agents, Parasympathetic-Blocking,Agents, Parasympatholytic,Drug, Antispasmodic,Drug, Parasympatholytic,Drugs, Antispasmodic,Drugs, Parasympatholytic,Effect, Antispasmodic,Effect, Parasympatholytic,Effects, Antispasmodic,Effects, Parasympatholytic,Parasympathetic Blocking Agent,Parasympathetic Blocking Agents
D002086 Butylscopolammonium Bromide Antimuscarinic quaternary ammonium derivative of scopolamine used to treat cramps in gastrointestinal, urinary, uterine, and biliary tracts, and to facilitate radiologic visualization of the gastrointestinal tract. Hyoscinbutylbromide,Scopolaminebutylbromide,Buscapine,Buscolysin,Buscopan,Butylscopolamine,Hyoscine N-Butylbromide,N-Butylscopolammonium Bromide,Scopolan,Bromide, Butylscopolammonium,Bromide, N-Butylscopolammonium,Hyoscine N Butylbromide,N Butylscopolammonium Bromide,N-Butylbromide, Hyoscine
D003287 Contrast Media Substances used to allow enhanced visualization of tissues. Radiopaque Media,Contrast Agent,Contrast Agents,Contrast Material,Contrast Materials,Radiocontrast Agent,Radiocontrast Agents,Radiocontrast Media,Agent, Contrast,Agent, Radiocontrast,Agents, Contrast,Agents, Radiocontrast,Material, Contrast,Materials, Contrast,Media, Contrast,Media, Radiocontrast,Media, Radiopaque
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis

Related Publications

G M Richter, and C Wunsch, and B Schneider, and M Düx, and E Klar, and R Seelos, and G W Kauffmann
January 1999, Journal of computer assisted tomography,
G M Richter, and C Wunsch, and B Schneider, and M Düx, and E Klar, and R Seelos, and G W Kauffmann
June 1992, Indian journal of cancer,
G M Richter, and C Wunsch, and B Schneider, and M Düx, and E Klar, and R Seelos, and G W Kauffmann
November 2005, European radiology,
G M Richter, and C Wunsch, and B Schneider, and M Düx, and E Klar, and R Seelos, and G W Kauffmann
August 1997, AJR. American journal of roentgenology,
G M Richter, and C Wunsch, and B Schneider, and M Düx, and E Klar, and R Seelos, and G W Kauffmann
October 2003, Cancer imaging : the official publication of the International Cancer Imaging Society,
G M Richter, and C Wunsch, and B Schneider, and M Düx, and E Klar, and R Seelos, and G W Kauffmann
February 1988, AJR. American journal of roentgenology,
G M Richter, and C Wunsch, and B Schneider, and M Düx, and E Klar, and R Seelos, and G W Kauffmann
January 1997, European radiology,
G M Richter, and C Wunsch, and B Schneider, and M Düx, and E Klar, and R Seelos, and G W Kauffmann
January 2005, Abdominal imaging,
G M Richter, and C Wunsch, and B Schneider, and M Düx, and E Klar, and R Seelos, and G W Kauffmann
August 2005, World journal of gastroenterology,
G M Richter, and C Wunsch, and B Schneider, and M Düx, and E Klar, and R Seelos, and G W Kauffmann
September 2002, AJR. American journal of roentgenology,
Copied contents to your clipboard!